Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Botulinum Toxin for Benign Prostatic Hyperplasia
NCT00451191Phase 2Completed
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases
- Start
- Oct 2006
- Primary completion
- Jun 2009
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of botulinum toxin type A in benign prostatic hyperplasia (BPH) (2 arms), sponsored by National Institute of Diabetes and Digestive and Kidney Diseases. Primary endpoint: Improvement in the AUA Symptom Score Index by 30% From Baseline at 12 weeks. Started Oct 2006; status: completed.
02
Drugs
botulinum toxin type A
03
Conditions
benign prostatic hyperplasia (BPH)
Beyond the preview
Go deeper on NCT00451191.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00451191.